
Carolyn Williamson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11240660/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	27.8	1,210
2	Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. Journal of Virological Methods, 2022, 302, 114471.	2.1	8
3	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Science Translational Medicine, 2022, 14, .	12.4	77
4	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 2022, 602, 654-656.	27.8	928
5	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nature Communications, 2022, 13, 1976.	12.8	27
6	Sixteen novel lineages of SARS-CoV-2 in South Africa. Nature Medicine, 2021, 27, 440-446.	30.7	326
7	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	27.8	1,381
8	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). New England Journal of Medicine, 2021, 384, 2161-2163.	27.0	111
9	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clinical Infectious Diseases, 2021, 73, 1528-1531.	5.8	4
10	Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa. Lancet Infectious Diseases, The, 2021, 21, 1354.	9.1	12
11	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	12.6	144
12	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host and Microbe, 2021, 29, 1611-1619.e5.	11.0	106
13	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathogens, 2021, 17, e1010046.	4.7	6
14	Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. Cell Reports, 2020, 33, 108430.	6.4	16
15	HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses. AIDS Research and Human Retroviruses, 2020, 36, 1010-1019.	1.1	0
16	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. MSphere, 2020, 5, .	2.9	3
17	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open, 2020, 10, e042247.	1.9	25
18	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 2019, 11, 607.	3.3	12

CAROLYN WILLIAMSON

#	Article	IF	CITATIONS
19	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Science Translational Medicine, 2019, 11, .	12.4	141
20	Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. Journal of Virology, 2019, 93, .	3.4	9
21	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Frontiers in Immunology, 2019, 10, 2875.	4.8	20
22	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. Journal of Virology, 2019, 93, .	3.4	13
23	Integrin α ₄ β ₇ expression on peripheral blood CD4 ⁺ T cells predicts HIV acquisition and disease progression outcomes. Science Translational Medicine, 2018, 10, .	12.4	85
24	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host and Microbe, 2018, 24, 593-599.e3.	11.0	24
25	Case report: mechanisms of HIV elite control in two African women. BMC Infectious Diseases, 2018, 18, 54.	2.9	82
26	Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. Journal of Virology, 2017, 91, .	3.4	13
27	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. Journal of Virology, 2017, 91, .	3.4	23
28	Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women. Aids, 2017, 31, 191-197.	2.2	2
29	Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. Journal of Virology, 2017, 91, .	3.4	35
30	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. Clinical Infectious Diseases, 2017, 64, 79-82.	5.8	53
31	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
32	From Bench to Bedside: Lessons from HIVÂNatural History Cohort Studies. , 2017, , 137-152.		0
33	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.7	150
34	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. Journal of Virology, 2016, 90, 10220-10235.	3.4	32
35	Metabolic Syndrome After HIV Acquisition in South African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 438-445.	2.1	26
36	Approaches to the induction of HIV broadly neutralizing antibodies. Current Opinion in HIV and AIDS, 2016, 11, 569-575.	3.8	15

#	Article	IF	CITATIONS
37	Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor. AIDS Research and Human Retroviruses, 2016, 32, 303-310.	1.1	3
38	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	4.7	81
39	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication. Retrovirology, 2015, 12, 54.	2.0	19
40	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 55-61.	2.1	10
41	Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends in Microbiology, 2015, 23, 204-211.	7.7	77
42	HIV-1 Superinfection Resembles Primary Infection. Journal of Infectious Diseases, 2015, 212, 904-908.	4.0	13
43	Genital Inflammation and the Risk of HIV Acquisition in Women. Clinical Infectious Diseases, 2015, 61, 260-269.	5.8	354
44	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nature Medicine, 2015, 21, 1332-1336.	30.7	215
45	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. Journal of Infectious Diseases, 2015, 211, 1461-1466.	4.0	7
46	Limited HIV-1 Superinfection in Seroconverters from the CAPRISA 004 Microbicide Trial. Journal of Clinical Microbiology, 2014, 52, 844-848.	3.9	14
47	Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8 ⁺ T Cell Responses on HIV Set Point. Journal of Virology, 2014, 88, 1819-1824.	3.4	36
48	Rapid Disease Progression in HIV-1 Subtype C–Infected South African Women. Clinical Infectious Diseases, 2014, 59, 1322-1331.	5.8	46
49	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	27.8	681
50	Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sexually Transmitted Infections, 2014, 90, 580-587.	1.9	173
51	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. Journal of Virology, 2014, 88, 12623-12643.	3.4	75
52	Epidemiology of HIV-1 Subtypes Among Men Who Have Sex With Men in Cape Town, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 473-480.	2.1	25
53	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. Journal of Virology, 2013, 87, 7218-7233.	3.4	119
54	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virology Journal, 2013, 10, 347.	3.4	14

CAROLYN WILLIAMSON

#	Article	IF	CITATIONS
55	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	4.7	190
56	Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies. Journal of Virology, 2013, 87, 4882-4894.	3.4	65
57	Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. Aids, 2013, 27, 507-518.	2.2	14
58	Challenges of Diagnosing Acute HIV-1 Subtype C Infection in African Women: Performance of a Clinical Algorithm and the Need for Point-of-Care Nucleic-Acid Based Testing. PLoS ONE, 2013, 8, e62928.	2.5	13
59	Genital Tract Inflammation During Early HIV-1 Infection Predicts Higher Plasma Viral Load Set Point in Women. Journal of Infectious Diseases, 2012, 205, 194-203.	4.0	67
60	Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness. Journal of Virology, 2012, 86, 13423-13433.	3.4	9
61	The HIV-1 Epidemic: Low- to Middle-Income Countries. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007187-a007187.	6.2	89
62	Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa. Journal of Infectious Diseases, 2012, 206, 6-14.	4.0	171
63	Increased Memory Differentiation Is Associated with Decreased Polyfunctionality for HIV but Not for Cytomegalovirus-Specific CD8+T Cells. Journal of Immunology, 2012, 189, 3838-3847.	0.8	18
64	Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 2012, 18, 1688-1692.	30.7	273
65	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. Journal of Virology, 2011, 85, 4828-4840.	3.4	441
66	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. Journal of Virology, 2011, 85, 3128-3141.	3.4	151
67	Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology, 2011, 411, 113-131.	2.4	26
68	Short Communication Decreased Incidence of Dual Infections in South African Subtype C-Infected Women Compared to a Cohort Ten Years Earlier. AIDS Research and Human Retroviruses, 2011, 27, 1167-1172.	1.1	7
69	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. Aids, 2010, 24, 819-831.	2.2	195
70	A rev1–vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev–vpu–env cassettes and reduces virion infectivity in pseudotyping assays. Virology, 2010, 397, 346-357.	2.4	20
71	Fluidity of HIV-1-Specific T-Cell Responses during Acute and Early Subtype C HIV-1 Infection and Associations with Early Disease Progression. Journal of Virology, 2010, 84, 12018-12029.	3.4	26
72	Association of HIV-Specific and Total CD8+ T Memory Phenotypes in Subtype C HIV-1 Infection with Viral Set Point. Journal of Immunology, 2009, 182, 4751-4761.	0.8	75

CAROLYN WILLIAMSON

#	Article	IF	CITATIONS
73	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. PLoS Pathogens, 2009, 5, e1000598.	4.7	213
74	Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. Journal of Virology, 2009, 83, 470-478.	3.4	63
75	HIV molecular epidemiology: transmission and adaptation to human populations. Current Opinion in HIV and AIDS, 2009, 4, 247-252.	3.8	27
76	Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection. Virology Journal, 2008, 5, 141.	3.4	4
77	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology, 2008, 82, 1860-1869.	3.4	142
78	Anaemia in Acute HIV-1 Subtype C Infection. PLoS ONE, 2008, 3, e1626.	2.5	15
79	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. PLoS ONE, 2008, 3, e1954.	2.5	175
80	Utilizing nucleic acid amplification to identify acute HIV infection. Aids, 2007, 21, 653-655.	2.2	11
81	Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. AIDS Research and Human Retroviruses, 2007, 23, 316-321.	1.1	25
82	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology, 2007, 368, 172-181.	2.4	45
83	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. Journal of Virology, 2006, 80, 11776-11790.	3.4	334
84	Incidence of HIVâ€1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIVâ€1 Subtype C–Infected Female Sex Workers. Journal of Infectious Diseases, 2004, 190, 1355-1359.	4.0	119
85	Dual HIV-1 infection associated with rapid disease progression. Lancet, The, 2004, 363, 619-622.	13.7	189
86	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. AIDS Research and Human Retroviruses, 2003, 19, 133-144.	1.1	113
87	Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. Journal of Virology, 2002, 76, 2233-2244.	3.4	111
88	Restriction fragment length polymorphism analysis for rapid gag subtype determination of human immunodeficiency virus Type 1 in South Africa. Journal of Virological Methods, 1999, 78, 51-59.	2.1	17
89	An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa. Aids, 1997, 11, 81-87.	2.2	118
90	HIV-1 subtypes in different risk groups in South Africa. Lancet, The, 1995, 346, 782.	13.7	44

#	ARTICLE	IF	CITATIONS
91	HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. Journal of Virology, 0, , .	3.4	0